|
gptkbp:instanceOf
|
antipsychotic medication
butyrophenone derivative
|
|
gptkbp:approvalYear
|
1958
|
|
gptkbp:approvedBy
|
gptkb:Belgium
|
|
gptkbp:ATCCode
|
N05AD01
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
injectable solution
|
|
gptkbp:brand
|
gptkb:Haldol
|
|
gptkbp:CASNumber
|
52-86-8
|
|
gptkbp:category
|
typical antipsychotic
butyrophenone
dopamine antagonist
|
|
gptkbp:contraindication
|
gptkb:Parkinson's_disease
coma
CNS depression
hypersensitivity to haloperidol
|
|
gptkbp:discoveredBy
|
gptkb:Paul_Janssen
|
|
gptkbp:discoveredIn
|
1958
|
|
gptkbp:eliminationHalfLife
|
14–37 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:hasMolecularFormula
|
C21H23ClFNO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
haloperidol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
constipation
QT prolongation
hypotension
sedation
dry mouth
extrapyramidal symptoms
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:synonym
|
gptkb:Haldol
gptkb:Haloperil
gptkb:Serenace
|
|
gptkbp:usedFor
|
schizophrenia
delirium
Tourette syndrome
acute psychosis
mania
nausea and vomiting
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|